prof. dr. Fritz Offner
- ORCID iD
- 0000-0003-4690-3603
Show
Sort by
-
Predicting cytogenetic risk in newly-diagnosed multiple myeloma patients using conventional whole-body MRI, spinal dynamic contrast-enhanced MRI and spinal diffusion-weighted imaging
-
Epcoritamab in patients with relapsed or refractory chronic lymphocytic leukemia : results from the phase 1b/2 EPCORE CLL-1 trial expansion cohort
-
Metabolic response rates of epcoritamab plus R-CHOP in patients with previously untreated (1L) high-risk diffuse large B-cell lymphoma, including double-hit/triple-hit lymphoma : updated EPCORE NHL-2 data
-
Efficacy of forimtamig, a GPRC5DxCD3 bispecific antibody, in patients with relapsed/refractory multiple myeloma (RRMM) : analysis of patient and disease-related factors associated with responses
(2023) CLINICAL LYMPHOMA MYELOMA & LEUKEMIA. In Clinical Lymphoma Myeloma & Leukemia 23(Supplement 2). p.S3-S4 -
Single cell multi-omic dissection of response and resistance to chimeric antigen receptor T cells against BCMA in relapsed multiple myeloma
(2023) CLINICAL LYMPHOMA MYELOMA & LEUKEMIA. In Clinical Lymphoma Myeloma & Leukemia 23(Supplement 2). p.S3-S3 -
ELARA trial update : long-term clinical outcomes and correlative efficacy analyses of tisagenlecleucel in patients with relapsed/refractory follicular lymphoma (R/R FL)
(2023) CLINICAL LYMPHOMA MYELOMA & LEUKEMIA. In Clinical Lymphoma Myeloma & Leukemia 23(Supplement 1). p.S534-S535 -
Epcoritamab plus R-CHOP in patients with previously untreated (1L) high-risk diffuse large B-cell lymphoma, including double-hit/triple-hit lymphoma : updated EPCORE NHL-2 data
(2023) CLINICAL LYMPHOMA MYELOMA & LEUKEMIA. In Clinical Lymphoma Myeloma & Leukemia 23(Supplement 1). p.S431-S432 -
Glofitamab monotherapy induces high complete response rates in patients with heavily pretreated relapsed/ refractory mantle cell lymphoma
(2023) AMERICAN JOURNAL OF HEMATOLOGY. In American Journal of Hematology 98(Supplement 5). p.S52-S53 -
Subcutaneous epcoritamab with R-CHOP in previously untreated high-risk diffuse large B-cell lymphoma, including double-hit/triple-hit lymphoma : updated results from EPCORE NHL-2
(2023) AMERICAN JOURNAL OF HEMATOLOGY. In American Journal of Hematology 98(Supplement 5). p.S50-S50 -
Long-term clinical outcomes and correlative efficacy analyses in patients (Pts) with relapsed/refractory (r/r) follicular lymphoma (FL) treated with tisagenlecleucel in the ELARA Trial
(2023) ONCOLOGY RESEARCH AND TREATMENT. In Oncology Research and Treatment 46(Supplement 5). p.306-308 -
Glofitamab monotherapy induces high complete response rates in patients with heavily pretreated Relapsed or Refractory (R/R) Mantle Cell Lymphoma (MCL)
(2023) ONCOLOGY RESEARCH AND TREATMENT. In Oncology Research and Treatment 46(Supplement 5). p.23-24 -
Blood plasma and FFPE derived total RNA seq dataset from DLBCL and PMBCL patients
(2023) -
- Miscellaneous
- open access
Patient-specific alterations in blood plasma cfRNA profiles enable accurate classification of cancer patients and controls
-
RNA extraction method impacts quality metrics and sequencing results in diffuse large B-cell lymphoma formalin-fixed paraffin-embedded tissue samples
-
Systemic mastocytosis with myeloid sarcoma and B-CLL : molecular and clonal heterogeneity in a rare case of SM-AHN
-
- Journal Article
- A1
- open access
Exploring the cell-free total RNA transcriptome in diffuse large B-cell lymphoma and primary mediastinal B-cell lymphoma patients as biomarker source in blood plasma liquid biopsies
-
- Journal Article
- A1
- open access
Crosstalk between glucocorticoid and mineralocorticoid receptors boosts glucocorticoid-induced killing of multiple myeloma cells
-
Pan-cancer blood plasma cell-free RNA profiles reveal cancer type and patient-specific changes
-
- Journal Article
- A1
- open access
The iR2 regimen (ibrutinib plus lenalidomide and rituximab) for relapsed/refractory DLBCL : a multicentre, non-randomised, open-label phase 2 study
-
- Miscellaneous
- open access
Knocking out CD70 rescues CD70-specific nanoCAR T cells from antigen induced exhaustion
-
- Journal Article
- A1
- open access
RNA extraction method impacts quality metrics and sequencing results in formalin-fixed, paraffin-embedded tissue samples
-
Systemic mastocytosis with myeloid sarcoma and B-CLL : molecular and clonal heterogeneity in a rare case of SM-AHN with review of literature
-
Isolated amyloidosis of the gastro-intestinal tract
-
Glofitamab monotherapy induces high complete response rates in patients with heavily pretreated relapsed or refractory mantle cell lymphoma
-
Five-year results and overall survival update from the phase 3 randomized study AUGMENT : lenalidomide plus rituximab (R-2) vs rituximab plus placebo in patients with relapsed/refractory indolent Non-Hodgkin lymphoma
-
CD19 4-1BBL (RO7227166) a novel costimulatory bispecific antibody can be safely combined with the T-Cell engaging bispecific antibody glofitamab in relapsed or refractory B-cell Non-Hodgkin lymphoma
-
Subcutaneous epcoritamab in combination with rituximab plus lenalidomide (R-2) for first-line treatment of follicular lymphoma : initial results from phase 1/2 trial
-
Long-term clinical outcomes and correlative efficacy analyses in patients (pts) with relapsed/refractory follicular lymphoma (r/r FL) treated with tisagenlecleucel in the ELARA trial
-
Intravenous and subcutaneous administration of RG6234, a novel GPRC5DxCD3 T-cell engaging bispecific antibody, is highly active in patients with relapsed/refractory multiple myeloma (RRMM) : biomarker results from a phase I study
-
RG6234, a GPRC5DxCD3 T-cell engaging bispecific antibody, is highly active in patients (pts) with relapsed/refractory multiple myeloma (RRMM) : updated intravenous (IV) and first subcutaneous (SC) results from a phase I dose-escalation study
-
- Miscellaneous
- open access
Many people with chronic lymphocytic leukemia or small lymphocytic lymphoma benefit from Ibrutinib treatment up to 8 years : a plain language summary
-
CD8 presence and dynamics in glofitamab-treated patients with relapsed/refractory B-cell Non-Hodgkin lymphoma using the CD8-specific PET tracer Zr-89-crefmirlimab berdoxam
-
- Journal Article
- A1
- open access
Combining Ixazomib with subcutaneous rituximab and dexamethasone in relapsed or refractory Waldenstrom's macroglobulinemia : final analysis of the phase I/II HOVON124/ECWM-R2 study
-
First-line treatment (Tx) with subcutaneous (SC) epcoritamab (epco) plus R-CHOP in patients (pts) with high-risk diffuse large B-cell lymphoma (DLBCL) : phase 1/2 data update
-
Glofitamab in patients with relapsed/refractory (R/R) diffuse large B-cell lymphoma (DLBCL) and >= 2 prior therapies : pivotal phase II expansion results
-
Subcutaneous epcoritamab plus R-DHAX/C in patients (pts) with relapsed or refractory (R/R) diffuse large B-cell lymphoma (DLBCL) eligible for autologous stem cell transplant (ASCT) : preliminary phase 1/2 results
-
- Journal Article
- A1
- open access
Inhibition of the protein arginine methyltransferase PRMT5 in high-risk multiple myeloma as a novel treatment approach
-
- Journal Article
- A1
- open access
Up to 8-year follow-up from RESONATE-2 : first-line ibrutinib treatment for patients with chronic lymphocytic leukemia
-
Effect of prior therapy and disease refractoriness on the efficacy and safety of oral selinexor in patients with diffuse large B-cell lymphoma (DLBCL) : a post-hoc analysis of the SADAL study
-
Glofitamab in patients with relapsed/refractory (R/R) diffuse large B-cell lymphoma (DLBCL) and >= 2 prior lines of therapy : key results of the phase-II expansion
(2022) ONCOLOGY RESEARCH AND TREATMENT. In Oncology Research and Treatment 45(Supplement 2). p.50-51 -
Glofitamab for relapsed or refractory diffuse large B-cell lymphoma
-
Tisagenlecleucel in adult relapsed or refractory follicular lymphoma : the phase 2 ELARA trial
-
- Journal Article
- A1
- open access
The association between patient characteristics and the efficacy and safety of selinexor in diffuse large B-cell lymphoma in the SADAL study
-
- Journal Article
- A1
- open access
Nucleic acid biomarkers in Waldenstrom Macroglobulinemia and IgM-MGUS : current insights and clinical relevance
-
A unique phenotype of longitudinal extensive transverse myelitis in autoimmune lymphoproliferative syndrome
-
- Journal Article
- A1
- open access
Real-world estimation of first- and second-line treatments for diffuse large B-cell lymphoma using health insurance data : a Belgian population-based study
-
Carfilzomib maintenance in newly diagnosed non-transplant eligible multiple myeloma
-
Cusatuzumab for treatment of CD70-positive relapsed or refractory cutaneous T-cell lymphoma
-
Comparison of the effectiveness and safety of the oral selective inhibitor of nuclear export, selinexor, in diffuse large B cell lymphoma subtypes
-
- Journal Article
- A1
- open access
Prolonged remissions after nivolumab plus gemcitabine/oxaliplatin in relapsed/refractory T-cell lymphoma
-
Identifying patients with chronic lymphocytic leukemia without need of treatment : end of endless watch and wait?
-
- Journal Article
- A1
- open access
Shallow-depth sequencing of cell-free DNA for Hodgkin and diffuse large B-cell lymphoma (differential) diagnosis : a standardized approach with underappreciated potential
-
- Conference Paper
- C3
- open access
Real world population-based study of treatment-modalities of diffuse large B-cell lymphoma in Belgium : focus on the older population
-
Nivolumab in combination with gemcitabine and oxaliplatin (GemOx) in relapse/refractory T-cell lymphoma : preliminary results of the experimental arm of the NIVEAU trial
(2021) ONCOLOGY RESEARCH AND TREATMENT. In Oncology Research and Treatment 44(supplement 2). p.128-129 -
Up to seven years of follow-up in the RESONATE-2 study of first-line ibrutinib treatment for patients with chronic lymphocytic leukemia
-
- Journal Article
- A1
- open access
Glofitamab, a novel, bivalent CD20-targeting T-cell-engaging bispecific antibody, induces durable complete remissions in relapsed or refractory B-cell lymphoma : a phase I trial
-
Glofitamab step-up dosing (SUD) : updated efficacy data show high complete response rates in heavily pretreated relapsed/refractory (R/R) non-Hodgkin lymphoma (NHL) patients (Pts)
(2021) CLINICAL LYMPHOMA MYELOMA & LEUKEMIA. In Clinical Lymphoma Myeloma & Leukemia 21(Supplement 1). p.S394-S394 -
Long-term follow-up, up to 7 years, in the RESONATE-2 study of first-line ibrutinib treatment for chronic lymphocytic leukemia (CLL)
(2021) CLINICAL LYMPHOMA MYELOMA & LEUKEMIA. In Clinical Lymphoma Myeloma & Leukemia 21(Supplement 1). p.S316-S316 -
When hematochezia becomes a red herring
-
Maintenance with daratumumab or observation following treatment with bortezomib, thalidomide, and dexamethasone with or without daratumumab and autologous stem-cell transplant in patients with newly diagnosed multiple myeloma (CASSIOPEIA) : an open-label, randomised, phase 3 trial
-
- Journal Article
- A1
- open access
Avelumab in combination regimens for relapsed/refractory DLBCL : results from the phase Ib JAVELIN DLBCL study
-
Real world application of R‐chop for diffuse large B‐cell lymphoma (DLBCL) in Belgium and its impact on survival
-
- Journal Article
- A1
- open access
Survival among patients with relapsed/refractory diffuse large B cell lymphoma treated with single-agent selinexor in the SADAL study
-
Stem cell yield and transplantation in transplant-eligible newly diagnosed multiple myeloma patients receiving daratumumab plus bortezomib/thalidomide/dexamethasone in the phase III CASSIOPEIA study
-
Oral ixazomib, lenalidomide, and dexamethasone for transplant-ineligible patients with newly diagnosed multiple myeloma
-
- Journal Article
- A1
- open access
Cyclin D2 overexpression drives B1a-derived MCL-like lymphoma in mice
-
- Journal Article
- A1
- open access
Health-related quality of life and utility outcomes with selinexor in relapsed/refractory diffuse large B-cell lymphoma
-
- Journal Article
- A1
- open access
Covalent cysteine targeting of Bruton's tyrosine kinase (BTK) family by withaferin-A reduces survival of glucocorticoid-resistant multiple myeloma MM1 cells
-
- Journal Article
- A1
- open access
Circulating RNA biomarkers in diffuse large B-cell lymphoma : a systematic review
-
Shallow whole-genome sequencing of cell-free DNA for B-cell lymphoma diagnosis and disease monitoring: a standardized approach with underappreciated potential
-
Shallow whole-genome sequencing of cell-free DNA for B-cell lymphoma diagnosis and disease monitoring : a standardized approach with underappreciated potential
(2020) -
Selinexor efficacy and safety are independent of renal function in patients with relapsed/refractory diffuse large B-cell lymphoma (DLBCL) : a post-hoc analysis from the pivotal phase 2b sadal study
-
Phase 1 study of CD19 targeted 4-1BBL costimulatory agonist to enhance T cell (glofitamab combination) or NK cell effector function (obinutuzumab combination) in relapsed/refractory B cell lymphoma
-
Effect of age on the efficacy and safety of single agent oral selinexor in patients with relapsed/refractory diffuse large B-cell lymphoma (DLBCL) : a post-hoc analysis of the sadal pivotal study
-
Nivolumab in combination with gemcitabine and oxaliplatin (GemOx) in relapse/refractory T-cell lymphoma : preliminary results of the experimental arm of the niveau trial
-
Efficacy and safety of tisagenlecleucel in adult patients with relapsed/refractory follicular lymphoma : interim analysis of the phase 2 ELARA trial
-
Health utility in relapsed/refractory diffuse large B-cell lymphoma (RR-DLBCL) patients : results of a phase II trial with oral selinexor
-
Selinexor in patients with relapsed or refractory diffuse large B-cell lymphoma (SADAL) : a single-arm, multinational, multicentre, open-label, phase 2 trial
-
Ixazomib plus lenalidomide-dexamethasone (IRd) vs. placebo-Rd for newly diagnosed multiple myeloma (NDMM) patients not eligible for autologous stem cell transplant : the double-blind, placebo-controlled, phase 3 TOURMALINE-MM2 trial
(2020) CLINICAL LYMPHOMA MYELOMA & LEUKEMIA. In Clinical Lymphoma Myeloma & Leukemia 20(Supplement 1). p.S307-S308 -
Glofitamab in relapsed or refractory (R/R) non-Hodgkin lymphoma (NHL) : durable complete responses and manageable safety observed at clinically relevant doses in Phase I dose escalation
(2020) ONCOLOGY RESEARCH AND TREATMENT. In Oncology Research and Treatment 43(Supplement 4). p.58-59 -
- Journal Article
- A1
- open access
Prognostic and predictive role of gene mutations in chronic lymphocytic leukemia : results from the pivotal phase III study COMPLEMENT1
-
- Journal Article
- A1
- open access
Latest perspectives on glucocorticoid-induced apoptosis and resistance in lymphoid malignancies
-
- Journal Article
- A1
- open access
Long-term efficacy and safety of first-line ibrutinib treatment for patients with CLL/SLL : 5 years of follow-up from the phase 3 RESONATE-2 study
-
Ibrutinib for first-line treatment of chronic lymphocytic leukemia in patients aged >= 65 year of age : results with 5 years of follow-up for the RESONATE-2 study
-
A five-year follow-up of untreated patients with chronic lymphocytic leukaemia treated with ofatumumab and chlorambucil : final analysis of the Complement 1 phase 3 trial
-
- Conference Paper
- C3
- open access
Real world population-based exploration of the pathology subtyping and treatment-modalities of diffuse large B-cell lymphoma in Belgium in relation to survival
-
Real world population-based exploration of the pathology subtyping and treatment-modalities of diffuse large B-cell lymphoma in Belgium in relation to survival
-
Dual CD20-targeted therapy with concurrent CD20-TCB and obinutuzumab shows highly promising clinical activity and manageable safety in relapsed or refractory B-cell non-Hodgkin lymphoma : preliminary results from a phase Ib trial
-
Implication of inherited genetic variants associated with follicular lymphoma susceptibility in the prognosis of patients treated by immunochemotherapy in PRIMA study
-
Effect of prior therapy on the efficacy and safety of oral Selinexor in patients with relapsed/refractory (R/R) diffuse large B-cell lymphoma (DLBCL) : a post-hoc analysis of the SADAL study
-
Exploring the potential of shallow whole-genome sequencing for diagnosis and disease monitoring of lymphoma in liquid biopsy
-
Phase 2 results of the iR(2) Regimen (Ibrutinib, Lenalidomide, and Rituximab) in patients with Relapsed/Refractory (R/R) Non-Germinal Center B Cell-like (Non-GCB) Diffuse Large B-Cell Lymphoma (DLBCL)
-
Ixazomib, Rituximab and Dexamethasone (IRD) in patients with relapsed or progressive Waldenstrom's macroblobulinemia : results of the prospective phase I/II hovon 124/Ecwm-R2 trial
-
Long-term follow-up of previously untreated patients (pts) with chronic lymphocytic leukemia (CLL) treated with ofatumumab (OFA) and chlorambucil (CHL) : final analysis of the phase 3 COMPLEMENT 1 trial.
-
Efficacy and time to next treatment following lenalidomide/rituximab (R-2) or rituximab/placebo in patients with R/R indolent NHL (AUGMENT)
-
Carfilzomib weekly plus melphalan and prednisone in newly diagnosed transplant-ineligible multiple myeloma (IFM 2012-03) : a phase I trial
-
- Journal Article
- A1
- open access
The use of murine models for studying mechanistic insights of genomic instability in multiple myeloma
-
A phase 2b study of selinexor in patients with Relapsed/Refractory (R/R) Diffuse Large B-Cell Lymphoma (DLBCL)
-
Characterization of duvelisib in patients with refractory marginal zone lymphoma : data from the phase 2 DYNAMO trial
-
Effect of dose modifications on response to duvelisib in patients with Relapsed/Refractory (R/R) CLL/SLL in the DUO trial
-
Five-year follow-up after ibrutinib therapy for first-line treatment of chronic lymphocytic leukemia
-
Phase 1 first-in-human trial of the anti-CD37 antibody BI 836826 in relapsed/refractory chronic lymphocytic leukemia
-
Lenalidomide/rituximab (R2) versus rituximab/placebo efficacy by POD24 status and time to next treatment in patients with relapsed/refractory indolent NHL (AUGMENT)
-
Effect of dose modifications on response to duvelisib in patients with relapsed or refractory chronic lymphocytic leukemia/small lymphocytic lymphoma in the DUO trial
-
Characterization of duvelisib in patients with refractory marginal zone lymphoma : data from the phase 2 DYNAMO trial
-
Sustained progression-free survival benefit of rituximab maintenance in patients with follicular lymphoma : long-term results of the PRIMA study
-
- Journal Article
- A1
- open access
Ofatumumab maintenance prolongs progression-free survival in relapsed chronic lymphocytic leukemia : final analysis of the PROLONG study
-
- Journal Article
- A1
- open access
The anaphase-promoting complex/cyclosome : a new promising target in diffuse large B-cell lymphoma and mantle cell lymphoma
-
Real world population-based exploration of the pathology subtyping and treatment-modalities of diffuse large B-cell lymphoma in Belgium in relation to survival
-
Oral ixazomib maintenance following autologous stem cell transplantation (TOURMALINE-MM3) : a double-blind, randomised, placebo-controlled phase 3 trial
-
Phase III randomized AUGMENT study of Lenalidomide/Rituximab vs Rituximab/Placebo in Patients with relapsed/refractory indolent non-hodgkin lymphoma
-
- Journal Article
- A1
- open access
AUGMENT : a phase III study of lenalidomide plus rituximab versus placebo plus rituximab in relapsed or refractory indolent lymphoma
-
Characterization of the long-term efficacy and safety of duvelisib monotherapy in patients with relapsed/refractory CLL/SLL on treatment for > 2 years across 4 clinical studies
-
The iR(2) regimen (ibrutinib, lenalidomide, and rituximab) is active with a manageable safety profile in patients with relapsed/refractory non-germinal center-like diffuse large B-cell lymphoma
-
AUGMENT : a phase III randomized study of lenalidomide plus rituximab (R-2) vs rituximab/placebo in patients with relapsed/refractory indolent non-Hodgkin lymphoma
-
CD20-Tcb (RG6026), a novel '' 2:1 '' format T-cell-engaging bispecific antibody, induces complete remissions in relapsed/refractory B-cell non-Hodgkin's lymphoma : preliminary results from a phase I first in human trial
-
Argx-110 for treatment of CD70-positive advanced cutaneous T-cell lymphoma in a phase 1/2 clinical trial
-
Proteomic characterization of Withaferin A-targeted protein networks for the treatment of monoclonal myeloma gammopathies
-
- Journal Article
- A1
- open access
Ibrutinib versus temsirolimus : 3-year follow-up of patients with previously treated mantle cell lymphoma from the phase 3, international, randomized, open-label RAY study
-
- Journal Article
- A1
- open access
Moxetumomab pasudotox in relapsed/refractory hairy cell leukemia
-
- Journal Article
- A1
- open access
Sustained efficacy and detailed clinical follow-up of first-line ibrutinib treatment in older patients with chronic lymphocytic leukemia : extended phase 3 results from RESONATE-2
-
The light chain IgLV3-21 defines a new poor prognostic subgroup in chronic lymphocytic leukemia : results of a multicenter study
-
The phase 3 DUO trial : duvelisib vs ofatumumab in relapsed and refractory CLL/SLL
-
- Journal Article
- A1
- open access
Central nervous system relapse in patients over 80 years with diffuse large B-cell lymphoma : an analysis of two LYSA studies
-
A gene-expression profiling score for prediction of outcome in patients with follicular lymphoma : a retrospective training and validation analysis in three international cohorts
-
- Journal Article
- A1
- open access
Effect of combining glucocorticoids with Compound A on glucocorticoid receptor responsiveness in lymphoid malignancies
-
Phase 1b/3 study of avelumab-based combination regimens in patients with relapsed or refractory diffuse large B-cell lymphoma (R/R DLBCL)
-
The impact of the updated IMWG diagnostic criteria in a real-life SMM cohort : a single center experience
-
Phase I dose-escalation study of the anti-CD70 antibody ARGX-110 in advanced malignancies
-
- Journal Article
- A1
- open access
Coregulator profiling of the glucocorticoid receptor in lymphoid malignancies
-
- Journal Article
- A1
- open access
Safety and efficacy of abexinostat, a pan-histone deacetylase inhibitor, in non-Hodgkin lymphoma and chronic lymphocytic leukemia : results of a phase II study
-
Clinical response observed in a phase I study in T cell lymphoma patients treated with anti-CD70 SIMPLE antibody ARGX-110
-
The mineralocorticoid receptor is involved in glucocorticoid resistance
-
A phase I study in T cell lymphoma patients treated with anti-CD70 simple antibody (TM) ARGX-110
-
IFM2012-03
-
Updated efficacy and safety from the phase 3 resonate-2 study : ibrutinib as first-line treatment option in patients 65 years and older with chronic lymphocytic leukemia/small lymphocytic leukemia
-
Carfilzomib and dexamethasone versus bortezomib and dexamethasone for patients with relapsed or refractory multiple myeloma (ENDEAVOR) : a randomised, phase 3, open-label, multicentre study
-
Daratumumab, lenalidomide, and dexamethasone for multiple myeloma
-
- Journal Article
- A2
- open access
Selective glucocorticoid receptor-activating adjuvant therapy in cancer treatments
-
International, randomized phase 3 study results : Ibrutinib versus Chlorambucil in patients 65 years and older with treatment-naive CLL (RESONATE-2 (TM))
-
Health-related quality of life and patient-reported outcomes of ofatumumab plus chlorambucil versus chlorambucil monotherapy in the COMPLEMENT 1 trial of patients with previously untreated CLL
-
A phase 2, multicenter study investigating ofatumumab and bendamustine combination in patients with untreated or relapsed CLL
-
Updated outcomes and impact of age with lenalidomide and low-dose dexamethasone or melphalan, prednisone, and thalidomide in the randomized, phase III FIRST trial
-
Ibrutinib combined with bendamustine and rituximab compared with placebo, bendamustine, and rituximab for previously treated chronic lymphocytic leukaemia or small lymphocytic lymphoma (HELIOS): a randomised, double-blind, phase 3 study
-
VANTAGE 095: an international, multicenter, open-label study of vorinostat (MK-0683) in combination with bortezomib in patients with relapsed and refractory multiple myeloma
-
A phase I study in T cell lymphoma patients treated with anti-CD70 simple antibody T ARGX-110
-
Improvement in quality of life and well-being in older patients with treatment-naive (TN) CLL : results from the randomized phase 3 study of ibrutinib (IBR) versus chlorambucil (CLB) (resonate-2™)
-
Carfilzomib weekly plus melphalan and prednisone in newly diagnosed elderly multiple myeloma (IFM 2012-03)
-
Randomized, double-blind, phase III trial of enzastaurin versus placebo in patients achieving remission after first-line therapy for high-risk diffuse large B-cell lymphoma
-
Risk factors and outcomes for patients with follicular lymphoma who had histologic transformation after response to first-line immunochemotherapy in the PRIMA trial
-
Mimicking the tumour microenvironment of chronic lymphocytic leukaemia in vitro critically depends on the type of B-cell receptor stimulation
-
Plasma exposure to metabolites of monomethyl auristatin E (MMAE) in patients with relapsed/refractory Hodgkin lymphoma (HL) treated with brentuximab vedotin (BV)
-
- Journal Article
- A1
- open access
Ibrutinib versus temsirolimus in patients with relapsed or refractory mantle-cell lymphoma: an international, randomised, open-label, phase study
-
Results from the international, randomized phase 3 study of ibrutinib versus chlorambucil in patients 65 years and older with treatment-naive (TN) CLL/SLL (RESONATE-2 (TM))
-
Improvement in hematologic function, disease burden/symptoms with ibrutinib in older treatment-naive (TN) patients with chronic lymphocytic leukemia (CLL) in phase 3 RESONATE-2 (TM)
-
Combined evaluation of conventional MRI, dynamic contrast-enhanced MRI and diffusion weighted imaging for response evaluation of patients with multiple myeloma
-
- Journal Article
- A2
- open access
Effect of prognostic classification on temsirolimus efficacy and safety in patients with relapsed or refractory mantle cell lymphoma : a retrospective analysis
-
A phase I dose-escalation study of antibody BI-505 in relapsed/refractory multiple myeloma
-
Carfilzomib weekly plus melphalan and prednisone in newly diagnosed elderly multiple myeloma (IFM 2012-03)
-
Results from the international, randomized phase 3 study of ibrutinib versus chlorambucil in patients 65 years and older with treatment-naive CLL/SLL (RESONATE-2 (TM))
-
Ibrutinib vs temsirolimus: results from a phase 3, international, randomized, open-label, multicenter study in patients with previously treated mantle cell lymphoma (MCL)
-
Chimeric antigen receptor transgenic, T cell receptor/CD3 negative monospecific T cells generated from cord blood CD34 positive cells
-
Frontline rituximab, cyclophosphamide, doxorubicin, and prednisone with bortezomib (VR-CAP) or vincristine (R-CHOP) for non-GCB DLBCL
-
Randomized phase II trial comparing obinutuzumab (GA101) with rituximab in patients with relapsed CD20⁺ indolent B-cell non-Hodgkin lymphoma: final analysis of the GAUSS study
-
Ibrutinib as initial therapy for patients with chronic lymphocytic leukemia
-
Combination of dexamethasone with the selective glucocorticoid receptor modulator, Compound A, does not enhance glucocorticoid responsiveness in lymphoid malignancies
-
Mimicking the tumor microenvironment of chronic lymphocytic leukemia in vitro critically depends on the type of B cell receptor stimulation
-
Telomere length and POT1 mutations in CLL: incidence, associations and clinical impact in the Complement 1 trial
-
Phase I, first-in-human trial of BI 836826 (an anti-CD37 antibody) in patients (PTS) with relapsed/refractory (R/R) chronic lymphocytic leukemia (CLL)
-
Effect of age on efficacy and safety outcomes in patients with newly diagnosed multiple myeloma receiving lenalidomide and low-dose dexamethasone (RD): the first trial
-
Health related quality of life and patient reported outcomes in patients receiving ofatumumab maintenance versus observation in the Prolong trial
-
Ofatumumab maintenance versus observation in relapsed chronic lymphocytic leukaemia (PROLONG): an open-label, multicentre, randomised phase 3 study
-
- Journal Article
- A1
- open access
Lipoprotein lipase SNPs rs13702 and rs301 correlate with clinical outcome in chronic lymphocytic leukemia patients
-
Chlorambucil plus ofatumumab versus chlorambucil alone in previously untreated patients with chronic lymphocytic leukaemia (COMPLEMENT 1): a randomised, multicentre, open-label phase 3 trial
-
Symptoms and toxicity of rituximab maintenance relative to observation following immunochemotherapy in patients with follicular lymphoma
-
Results of a phase II study of bendamustine and ofatumumab in untreated indolent B cell non-Hodgkin's lymphoma
-
Overall survival of relapsed and refractory multiple myeloma patients after adjusting for crossover in the MM-003 trial for pomalidomide plus low-dose dexamethasone
-
Pomalidomide plus low-dose dexamethasone (POM plus LoDEX) versus high-dose dexamethasone (HiDEX) for relapsed or refractory multiple myeloma (RRMM): overall survival (OS) results of MM-003 after adjustment for Res crossover
-
DUO: a phase 3 trial of the PL3K-delta,gamma inhibitor IPI-145 versus ofatumumab in patients with relapsed or refractory chronic lymphocytic leukemia or small lymphorytic lymphoma
-
A phase I first-in-human study of ARGX-110, a monoclonal antibody targeting CD70, a receptor involved in immune escape and tumor growth in patients with solid and hematologic malignancies
-
Ofatumumab (OFA) maintenance prolongs PFS in relapsed CLL: prolong study interim analysis results
-
Effect of age on efficacy and safety outcomes in patients (Pts) with newly diagnosed multiple myeloma (NDMM) receiving lenalidomide and low-dose dexamethasone (Rd): the first trial
-
Gene mutations and treatment outcome in CLL patients treated with chlorambucil (Chl) or ofatumumab-Chl (O-Chl): results from the phase III study COMPLEMENT1 (OMB110911)
-
Polyfunctional tumor antigen-specific T cells generated in vitro from human CD34 positive precursor cells transduced to express T cell receptor alpha beta chains fused to CD28-CD3 zeta signaling cassette
-
Phase IA/II, multicentre, open-label study of the CD40 antagonistic monoclonal antibody lucatumumab in adult patients with advanced non-Hodgkin or Hodgkin lymphoma
-
- Journal Article
- A1
- open access
Peripheral blood involvement in patients with follicular lymphoma: a rare disease manifestation associated with poor prognosis
-
SF3B1 mutations and outcome in CLL patients treated with chlorambucil (CHL) or ofatumumab-CHL (O plus CHL): results from the phase III study complement 1 (OMB110911)
-
Overall survival of patients with relapsed and refractory multiple myeloma: adjusting for crossover in the MM-003 trial for pomalidomide plus low-dose dexamethasone vs. high-dose dexamethasone
-
Abexinostat (S78454) a histone deacetylase inhibitor, in patients with refractory or relapsed Hodgkin's lymphoma, non-Hodgkin lymphoma and chronic lymphocytic leukaemia: preliminary phase II results
-
- Journal Article
- A1
- open access
Quantitative proteomics to characterize specific histone H2A proteolysis in chronic lymphocytic leukemia and the myeloid THP-1 cell line
-
NOTCH1 mutation and treatment outcome in CLL patients treated with chlorambucil (Chl) or ofatumumab-chi (O-Chl): results from the phase III study complement 1 (OMB110911)
-
Updated 6 year follow-up of the PRIMA study confirms the benefit of 2-year rituximab maintenance in follicular lymphoma patients responding to frontline immunochemotherapy
-
Ofatumumab plus chlorambucil versus chlorambucil alone in patients with untreated chronic lymphocytic leukemia (CLL): results of the phase III study complement 1 (OMB110911)
-
Safety profile and clinical response to MEDI-551, a humanized monoclonal anti-CD19, in a phase 1/2 study in adults with relapsed or refractory advanced B-cell malignancies
-
A phase III study of enzastaurin in patients with high-risk diffuse large B cell lymphoma following response to primary treatment: the prelude trial
-
SAR245409 Monotherapy in relapsed/refractory follicular lymphoma: preliminary results from the phase II ARD12130 study
-
Prespecified candidate biomarkers identify follicular lymphoma patients who achieved longer progression-free survival with bortezomib-rituximab versus rituximab
-
Efficacy and toxicity of two schedules of bortezomib in patients with recurrent or refractory follicular lymphoma: a randomised phase II trial from the Groupe d'Etude des Lymphomes de l'Adulte (GELA)
-
Safety and clinical activity of a combination therapy comprising two antibody-based targeting agents for the treatment of non-Hodgkin lymphoma: results of a phase I/II study evaluating the immunoconjugate inotuzumab ozogamicin with rituximab
-
ER stress in diffuse large B cell lymphoma: GRP94 is a possible biomarker in germinal center versus activated B-cell type
-
Early recognition of malignant lactic acidosis in clinical practice: report on 6 patients with haematological malignancies
-
Clinical outcome of patients with follicular lymphoma receiving chemoimmunotherapy in the PRIMA study is not affected by FCGR₃A and FCGR₂A polymorphisms
-
High-risk clonal evolution in chronic B-lymphocytic leukemia: single-center interphase fluorescence in situ hybridization study and review of the literature
-
Lenalidomide in relapsed refractory myeloma patients: impact of previous response to bortezomib and thalidomide on treatment efficacy: results of a medical need program in Belgium
-
Myeloma of the central nervous system: report of a single center case series
-
- Conference Paper
- C3
- open access
Neutrophil elastase is the 'histone H2A-specific protease'
-
Phase 2 studies of immunochemotherapy +/- bortezomib (VC) in newly diagnosed non-germinal center B-cell-like (GCB) DLBCL: rapid prospective identification of non-GCB patients (PTS)
-
Outcome in critically ill patients with allogeneic BM or peripheral haematopoietic SCT : a single-centre experience
-
Rituximab maintenance therapy for follicular lymphoma: reply
-
Rituximab maintenance for 2 years in patients with high tumour burden follicular lymphoma responding to rituximab plus chemotherapy (PRIMA): a phase 3, randomised controlled trial (vol 377, pg 42, 2011)
-
Identification of an Ire1alpha endonuclease specific inhibitor with cytotoxic activity against human multiple myeloma
-
Rituximab maintenance for 2 years in patients with high tumour burden follicular lymphoma responding to rituximab plus chemotherapy (PRIMA): a phase 3, randomised controlled trial
-
Pattern of infections observed during the maintenance phase in the PRIMA study
-
Impact of induction chemotherapy regimen on response, safety and outcome in the PRIMA study
-
Efficacy and safety of bortezomib-rituximab (VCR) vs rituximab® in patients (PTS) with relapsed, R-naive/-sensitive follicular lymphoma (FL): outcome according to prior therapy
-
Time to next anti-lymphoma therapy (TTNT) and treatment-free interval (TFI) with bortezomib-rituximab (VCR) vs rituximab® in patients (PTS) with relapsed follicular lymphoma (FL)
-
FCGR3A polymorphism does not significantly affect response and outcome of follicular lymphoma patients treated in the PRIMA study with rituximab and chemotherapy followed by rituximab maintenance or observation
-
Bortezomib plus rituximab versus rituximab alone in patients with relapsed, rituximab-naive or rituximab-sensitive, follicular lymphoma: a randomised phase 3 trial
-
Laser microdissection for the assessment of the clonal relationship between chronic lymphocytic leukemia/small lymphocytic lymphoma and proliferating B cells within lymph node pseudofollicles
-
Rituximab maintenance for 2-years significantly improves the outcome of patients with untreated high tumor burden follicular lymphoma after response to immunochemotherapy: results of the PRIMA study
-
Anti-CD22 immunoconjugate inotuzumab ozogamicin (CMC-544) + rituximab: clinical activity in patients with relapsed/refractory follicular or 'aggressive' lymphoma
-
The impact of the initial ventilatory strategy on survival in hematological patients with acute hypoxemic respiratory failure
-
Aspiration pneumonia : an underestimated cause of severe respiratory failure in patients with haematological malignancies and severe oral mucositis?
-
Impact of organ dysfunction on mortality in ICU patients with hematologic malignancies
-
The flavonoid tangeretin activates the unfolded protein response and synergizes with imatinib in the erythroleukemia cell line K562
-
Anti-CD22 immunoconjugate inotuzumab ozogamicin (CMC-544) + rituximab: clinical activity including survival in patients with recurrent/refractory follicular or 'aggressive' lymphoma
-
Phase III Study to Evaluate Temsirolimus Compared With Investigator's Choice Therapy for the Treatment of Relapsed or Refractory Mantle Cell Lymphoma
-
Xanthohumol activates the proapoptotic arm of the unfolded protein response in chronic lymphocytic leukemia
-
Steroid effects on ZAP-70 and SYK in relation to apoptosis in poor prognosis chronic lymphocytic leukemia
-
Chronic Lymphocytic Leukaemia
-
The prenylated chalcone xanthohumol induces unfolded protein response, autophagy, and cell death in breast cancer cells by proteasome inhibition
-
Spectrum of imaging findings in suspected multiple myeloma usisng dynamic contrast-enhanced and whole body MRI
-
Impact of recent intravenous chemotherapy on outcome in severe sepsis and septic shock patients with hematological malignancies
-
Xanthohumol: a new potential proteasome inhibitor that activates the pro-apoptotic arm of the unfolded protein response in B-CLL cells
-
A combined case report of 4 adult patients with hemophagocytic lymphohistiocytosis at the Ghent University Hospital in 2006
-
The anti-invasive and proapoptotic effect of xanthohumol: potential use in cancer.
-
Levetiracetam and bleeding disorders
-
Treatment of follicular lymphoma - A review
-
The endoplasmic reticulum: A target for new anticancer drugs
-
Xanthohumol induces in vitro apoptosis in B-CLL cells mediated by non-classical ER stress
-
Methylprednisolone downregulates ZAP-70 expression in B-CLL cells in vitro
-
Prognostic significance of lipoprotein lipase expression in B-cell chronic lymphocytic leukemia
-
B-CLL cells from lymph nodes express higher ZAP-70 levels than B-CLL cells from peripheral blood
-
Deguelin inhibits expression of I kappa B alpha protein and induces apoptosis of B-CLL cells in vitro
-
Lipoprotein lipase mRNA expression in whole blood is a prognostic marker in B cell chronic lymphocytic leukemia
-
Outcome in severely ill patients with hematological malignancies who received intravenous chemotherapy in the intensive care unit
-
In vitro screening for synergism of high-linear energy transfer Bi-213-radiotherapy with other therapeutic agents for the treatment of B-Cell chronic lymphocytic leukemia
-
EBV negative Richter's syndrome from a coexistent clone after salvage treatment with alemtuzumab in a CLL patient
-
Kolmogorov-Smirnov statistical test for analysis of ZAP-70 expression in B-CLL, compared with quantitative PCR and IgVH mutation status
-
Efficacy and safety of rituximab in B-cell post-transplantation lymphoproliferative disorders: results of a prospective multicenter phase 2 study